Lomonitinib

N/A

Report date: 2024/06/11 17:35:30
NME

Base Information

Drug NameLomonitinib
Drug Alias NameZE46-0134ZE-46-0134ZE-460134
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsInterleukin-1 receptor-associated kinase 4 inhibitors
TargetsTyrosine-protein kinase receptor FLT3Interleukin-1 receptor-associated kinase 4
Therapy Area/IndicationsLeukemia, Promyelocytic, AcuteLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEilean Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesLomond Therapeutics Holdings IncEilean Therapeutics LLC
Inactive CompaniesN/A
Active IndicationsLeukemia, Promyelocytic, AcuteLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A